Considerations on blood glucose management in type 2 diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 4, 2002, Pages 273-285

  Home, Philip ^a,g   Chacra, Antonio ^b   Chan, Juliana ^c   Emslie Smith, Alistair ^d   Sorensen, Lea ^e   Van Crombrugge, Paul ^f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Wallacetown Health Centre   (United Kingdom)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f OLV HOSPITAL   (Belgium)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Blood glucose; Communication; Education; Individualisation; Intensive diabetes management

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED PROTEIN; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

AGE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; COMORBIDITY; DEVICE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE PREDISPOSITION; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; HEALTH CARE NEED; HUMAN; HYPOGLYCEMIA; INDIVIDUALIZATION; INTERPERSONAL COMMUNICATION; LIFE EXPECTANCY; LONG TERM CARE; MEASUREMENT; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SOCIAL ENVIRONMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; COMMUNICATION; DIABETES MELLITUS, TYPE 2; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PATIENT EDUCATION; POSTPRANDIAL PERIOD;

EID: 0036657171     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.312     Document Type: Review

References (94)

1. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-107.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. UK Prospective Diabetes Study (UKPDS) Group. Overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes 1995; 44: 1249-1258.
6. Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40(Suppl.): S21-S25.
7. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
8. Muggeo M. Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. Diabet Med 1998; 15(Suppl.): S60-S62.
9. Jarrett RJ. Duration of non-insulin-dependent diabetes and development of retinopathy: analysis of possible risk factors. Diabet Med 1986; 3: 261-263.
10. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
11. Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997; 350: 1505-1510.
12. Masson EA, MacFarlane IA, Power E, Wallymahmed M. An audit of the management and outcome of hospital inpatients with diabetes: resource planning implications for the diabetes care team. Diabet Med 1992; 9: 753-755.
13. Marsiaj HI, Catalano C, Sum CF, Home PD, Alberti KG. Management of newly diagnosed non-insulin-dependent (Type 2) diabetes mellitus: a retrospective audit. Diabetes Res Clin Pract 1991; 12: 129-136.
14. European Diabetes Policy Group. Guidelines for diabetes care. A desktop guide to Type 1 (insulin-dependent) diabetes mellitus. Diabetes Nutr Metab 1999; 12: 345-378.
15. European Diabetes Policy Group. Guidelines for diabetes care. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
16. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
17. UK Prospective Diabetes Study (UKPDS) Group. Association of glycemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study (UKPDS 35). BMJ 2000; 321: 405-412.
18. Stott A, Casson IF, Higgins GJ. Glycated haemoglobin assays. Approaches to standardization of results. Diabet Med 2001; 18: 274-279.
19. 1c, standardization. Ann Clin Biochem 2000; 37(Pt 1): 47-48.
20. Benjamin RJ, Sacks DB. Glycated protein update: implications of recent studies, including the Diabetes Control and Complications Trial. Clin Chem 1994; 40: 683-687.
21. Weycamp CW, Penders TJ, Muskiet FA, van der Slik W. Evaluation of a reference material for glycated haemoglobin. Eur J Clin Chem Clin Biochem 1996; 34: 67-72.
22. Colman PG, Goodall GI, Garcia-Webb P, et al. Glycohaemoglobin: a crucial measurement in modern diabetes management. Progress towards standardisation and improved precision of measurement. Australian Diabetes Society, the Royal College of Pathologists of Australasia and the Australasian Association of Clinical Biochemists [Consensus Development Conference]. Med J Aust 1997; 21: 16796-16798.
23. Mosca A, Paleari R, Trapolino A, et al. A re-evaluation of glycohemoglobin standardisation: the Italian experience with 119 laboratories and 12 methods. Eur J Clin Chem Clin Biochem 1997; 35: 243-248.
24. National Glycohemoglobin Standardization Program Steering Committee. Implementation of the National Glycohemoglobin Standardization Program (NGSP). Diabetes 1997; 46(Suppl.1): 151A.
25. 1c: clinical and biological agreement for standardization of assay methods. Report by the experts of ALFEDIAM (Association de Langue Frana̧ise pour l'Etude du Diabete et des Maladies Metabolique) and SFBC (Société Frana̧ise de Biologie Clinique) [French]. Diabetes Metab 1999; 25: 283-367.
26. 1c measurements - a consensus statement. Diabet Med 2000; 17: 5-6.
27. 1c based on peptide mapping. Clin Chem 1997; 43: 1944-1951.
28. 1c determinations. Clin Chem Lab Med 1998; 36: 299-308.
29. 1c levels improves glycemic control in Type 1 and insulin-treated Type 2 diabetic patients. Diabetes Care 1999; 22: 1785-1789.
30. Martina WV, Martijn EG, van der Molen M, et al. β-N-Terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. Clin Chem 1993; 39: 2259-2265.
31. Weycamp CW, Penders TJ, Muskiet FAJ, van der Slik W. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993; 39: 1717-1723.
32. Krause JR, Stolc V, Campbell E. The effect of hemoglobin F upon glycosylated hemoglobin determinations. Am J Clin Pathol 1982; 78: 767-769.
33. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995; 18: 896-909.
34. Defallah AA, Eskandarani H, Rehaimi A, et al. Fructosamine in HbS- and G6PD-deficient Saudi Arabs in the Eastern Province of Saudi Arabia. Br J Biomed Sci 1994; 51: 332-335.
35. Constanti C, Simo JM, Joven J, et al. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: the influence of hypoalbuminaemia and hypergammaglobulinaemia. Ann Clin Biochem 1992; 29: 437-442.
36. Islam N, Akhter J, Kayani N, et al. Fructosamine: an alternative assessment of past glycaemic control in developing countries. J Pak Med Assoc 1993; 43: 238-240.
37. Lin MJ, Hoke C, Ettinger B, et al. Technical performance evaluation of BM/Hitachi 747-200 serum fructosamine assay. Clin Chem 1996; 42: 244-248.
38. 1c in the management of type 2 diabetes (NIDDM). Scand J Prim Health Care 1994; 12: 219-224.
39. Shield JP, Poysner K, Hunt L, et al. Fructosamine and glycated haemoglobin in the assessment of long term glycaemic control in diabetes. Arch Dis Child 1994; 71: 443-445.
40. Tvorogova MG, Zaitseva DTM, Aronskaia EE, et al. Comparison of fructosamine, glycosylated hemoglobin and glucose in patients with type II diabetes. Klin Lab Diagn 1995; 1: 10-12.
41. Hom FG, Ettinger B, Lin MJ. Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population. Acta Diabetol 1998; 35: 48-51.
42. 1c methods for monitoring diabetes in pregnancy. Ann Clin Biochem 1998, 35: 283-289.
43. Hughes PF, Agerwal M, Newman P, et al. An evaluation of fructosamine estimation in screening for gestational diabetes mellitus. Diabet Med 1995; 2: 708-712.
44. 1c and fructosamine concentrations in diagnosis of gestational diabetes mellitus. Clin Exp Obstet Gynecol 1995; 22: 230-234.
45. Meneilly GS, Tessier D. Diabetes in the elderly. Diabet Med 1995; 12: 949-960.
46. Austin GE, Wheaton R, Nanes MS, et al. Usefulness of fructosamine for monitoring outpatients with diabetes. Am J Med Sci 1999; 318: 316-323.
47. Petitti DB, Contreras R, Dudl J. Randomized trial of fructosamine home monitoring in patients with diabetes. Eff Clin Pract 2001; 4: 18-23.
48. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of Type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000; 23: 45-50.
49. Verges B. Impact de la regulation du glucose post-prandial en pratique. [The impact of regulation of postprandial glucose in practice.] Diabetes Metab 1999; 25(Suppl. 7): 22-25.
50. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-1826.
51. Soonthorpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract 1999; 46: 23-27.
52. 1c interrelationships in Type 2 diabetes. Diabetes Care 2001; 24: 2023-2029.
53. 1c. Diabetes Care 2000; 23: 1239-1241.
54. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333: 1237-1241.
55. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet 1976; 2: 1009-1012.
56. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987; 36: 689-692.
57. Pettitt DJ, Knowler WC, Lisse JR, Bennett PH. Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians. Lancet 1980; 2: 1050-1052.
58. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetes Med 1998; 15: 188-193.
59. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
60. de Vegt F, Dekker JM, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia 1999; 42: 926-931.
61. Owens DR. Repaglinide - prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 1998; 15(Suppl. 4): S28-S36.
62. Home PD, Barrioncanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue insulin aspart in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
63. Kalbag J, Hirschberg Y, McLeod JF, et al. Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects. Diabetes 1999; 48(Suppl. 1): Abstract 456.
64. Simpson KL, Spencer CM. Insulin aspart. Drugs 1999; 57: 759-767.
65. American Diabetes Association (ADA). Postprandial blood glucose. Diabetes Care 2001; 24: 775-778.
66. Bolinder J, Hagström-Toft E, Ungerstedt U, Arner P. Type I diabetic patients: comparison with continuous microdialysis measurements of glucose in subcutaneous adipose tissue during ordinary life conditions. Diabetes Care 1997; 20: 64-70.
67. Kennedy L. Self-monitoring of blood glucose in type 2 diabetes. Diabetes Care 2001; 24: 977-978.
68. Feleke Y, Abdulkadir J. Urine glucose testing: another look at its relevance when blood glucose monitoring is unaffordable. Ethiop Med J 1998; 36: 93-99.
69. Chadha V, Garg U, Alon US. Measurement of urinary concentration: a critical appraisal of methodologies. Pediatr Nephrol 2001; 16: 374-382.
70. McCarthy J. Value of urine glucose tests in the management of type II diabetes mellitus. Results of a study of the double-void technique. Postgrad Med 1984; 76: 204-210.
71. Gæde P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 randomised study. Lancet 1999; 353: 617-622.
72. American Diabetes Association (ADA). Clinical Practice Recommendations 2001: standards of medical care for patients with diabetes mellitus. Diabetes Care 2001; 24(Suppl. 1): S33-S43.
73. American Diabetes Association (ADA). Third-party reimbursement for diabetes care, self-management education, and supplies. Diabetes Care 2001; 24(Suppl. 1): S120-S121.
74. Mensing C, Boucher J, Cypress M, et al. National standards for diabetes self-management education. Diabetes Care 2001; 24(Suppl. 1): S126-S133.
75. Norris SL, Engelgau MM, Venkat Narayan KM. Effectiveness of self-management training in type 2 diabetes. Diabetes Care 2001; 24: 561-587.
76. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. Q J Med 2000; 93: 369-374.
77. Padgett D, Mumford E, Hynes M, Carter R. Meta-analysis of the effects of educational and psychosocial intervention of diabetes mellitus. J Clin Epidemiol 1988; 41: 1007-1030.
78. Korhonen T, Huttunen JK, Aro A, et al. A controlled trial on the effects of patient education in the treatment of insulin-dependent diabetes. Diabetes Care 1983; 6: 256-261.
79. Wisdom K, Fryzek JP, Havstad SL, et al. Comparison of laboratory test frequency and test results between African-Americans and Caucasians with diabetes: opportunities for improvement. Findings from a large urban health maintenance organization. Diabetes Care 1997; 20: 971-977.
80. Schneider SH, Ruderman NB. Exercise and NIDDM [Technical Review]. Diabetes Care 1990; 13: 785-789.
81. Franz MJ, Horton ES, Bantle JP, et al. Nutrition principles for the management of diabetes and related complications. Diabetes Care 1994; 17: 490-518.
82. Zinker BA. Nutrition and exercise in individuals with diabetes. Clin Sports Med 1999; 18: 585-606.
83. Paisey RB, Harvey P, Rice S, et al. An intensive weight loss programme in established Type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year. Diabet Med 1998; 15: 73-79.
84. Perry TL, Mann JI, Lewis-Barned NJ, et al. Lifestyle intervention in people with insulin-dependent diabetes mellitus (IDDM). Eur J Clin Nutr 1997; 51: 757-763.
85. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with diabetes for glucose control. Diabetes Care 1998; 21: 1644-1651.
86. Kirkman MS, Weinberger M, Landsman PB, et al. A telephone-delivered intervention for patients with NIDDM. Diabetes Care 1994; 17: 840-846.
87. Piette JD, Weinberger M, Kraemer FB, McPhee SJ. Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a Department of Veterans Affairs Health Care System: a randomized controlled trial. Diabetes Care 2001; 24: 202-208.
88. Estey AL, Tan MH, Mann K. Follow-up intervention: its effect on compliance behavior to a diabetes regimen. Diabetes Educ 1990; 16: 291-295.
89. Weinberger M, Kirkman MS, Samsa GP, et al. A nurse-coordinated intervention for primary care patients with non-insulin dependent diabetes mellitus. J Gen Intern Med 1995; 10: 59-66.
90. Lawson ML, Frank MR, Fry MK, et al. Intensive diabetes management in adolescents with Type 1 diabetes: the importance of intensive follow-up. J Pediatr Endocrinol Metab 2000; 13: 79-84.
91. Larme AC, Pugh JA. Attitudes of primary care providers toward diabetes. Diabetes Care 1998; 21: 1391-1396.
92. Feder G, Griffiths C, Highton C, et al. Do clinical guidelines introduced with practice-based education improve care of asthmatic and diabetic patients? A randomised controlled trial in general practices in east London. BMJ 1995; 311: 1473-1478.
93. American Diabetes Association (ADA). Clinical Practice Recommendations 2002: standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(Suppl. 1): S33-S49.
94. Levetan CS, Dawn KR, Want LL, et al. Glycated hemoglobin: 24-hour recall for its different names. Diabetes 2000; 49(Suppl. 1): A176.